U.S. market Closed. Opens in 1 day 12 hours 23 minutes

ABOS | Acumen Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.7500 - 1.8600
52 Week Range 1.7150 - 5.09
Beta -0.27
Implied Volatility 348.55%
IV Rank 42.67%
Day's Volume 745,754
Average Volume 227,741
Shares Outstanding 60,079,800
Market Cap 111,147,630
Sector Healthcare
Industry Biotechnology
IPO Date 2021-07-01
Valuation
Profitability
Growth
Health
P/E Ratio -1.34
Forward P/E Ratio -7.30
EPS -1.38
1YR Price Target 16.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 51
Country USA
Website ABOS
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.
*Chart delayed
Analyzing fundamentals for ABOS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ABOS Fundamentals page.

Watching at ABOS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ABOS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙